Shihabi S, Belani C P
University of Pittsburgh Cancer Institute, Pittsburgh, PA 15213, USA.
Clin Lung Cancer. 2001 May;2(4):275-81. doi: 10.3816/clc.2001.n.010.
Lung cancer continues to be the leading cause of cancer-related death in the United States. Small-cell lung cancer constitutes 15%-20% of all cases of lung cancer. It is a chemosensitive disease with an overall response rate of 70%-90% in first-line treatment. However, the majority of patients relapse, and further treatment at that time is unlikely to achieve a durable response. Among the new drugs studied in this disease, topoisomerase I inhibitors are emerging as active agents with significant activity in both untreated and relapsed disease. This paper reviews the current status of irinotecan and topotecan in the treatment of small-cell lung cancer.
肺癌仍然是美国癌症相关死亡的主要原因。小细胞肺癌占所有肺癌病例的15%-20%。它是一种对化疗敏感的疾病，一线治疗的总体缓解率为70%-90%。然而，大多数患者会复发，而且此时进一步治疗不太可能获得持久缓解。在针对该疾病研究的新药中，拓扑异构酶I抑制剂正在成为在未治疗和复发疾病中均具有显著活性的有效药物。本文综述了伊立替康和拓扑替康在小细胞肺癌治疗中的现状。
